Table 4.
Estimated means (SE) and estimated change scores across time for menopausal symptoms for women randomized to Stellate Ganglion Blockade (SGB) or placebo.
| Treatment Group | Treatment Group × Time (Δ baseline to 3 weeks) | Treatment Group × Time (Δ baseline to 3 months) | ||||
|---|---|---|---|---|---|---|
| SGB (n=20) | Sham-control (n=20) | |||||
|
| ||||||
| Δ Baseline to 3 weeks |
Δ Baseline to 3 months |
Δ Baseline to 3 weeks |
Δ Baseline to 3 months |
|||
| Outcomes | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) |
| Depressive Symptoms (CES-D) | −2.25 (1.31)T | −2.45 (1.26)‡ | 0.05 (1.38) | 1.06 (1.29) | −2.30 (1.91) | −3.51 (1.81)‡ |
| Utian Quality of Life (UQOL) | ||||||
| Total | 2.42 (1.91) | 0.53 (1.84) | −0.34 (2.01) | −1.85 (1.88) | 2.76 (2.77) | 2.39 (2.63) |
| Pittsburgh Sleep Quality Index (PSQI) | ||||||
| Global Score | 0.51 (0.79) | −0.97 (0.76) | −0.12 (0.86) | −0.59 (0.76) | 0.63 (1.17) | −0.38 (1.08) |
Note.
‡
p=0.06;
T
p=0.09; B=Beta; SE=Standard Error of Beta; Δ=change in score between two time-points; SGB=Stellate Ganglion Blockade. CES-D = Center for Epidemiological Studies Depression Scale. PSQI and CES-D: higher is more severe symptoms; UQOL: higher is less severe symptoms.